PRESS RELEASE published on 06/10/2024 at 23:22, 5 months 10 days ago GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis GENFIT achieves historic milestone with U.S. FDA accelerated approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis. Elafibranor tablets approved as first-in-class treatment, marking a significant development in rare liver disease treatment landscape Primary Biliary Cholangitis GENFIT Ipsen Iqirvo FDA Accelerated Approval
BRIEF published on 05/29/2024 at 22:15, 5 months 22 days ago GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 Research Collaboration GENFIT ACLF EASL Congress Liver Disease
PRESS RELEASE published on 05/29/2024 at 22:10, 5 months 22 days ago GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 GENFIT to present latest ACLF research at EASL Congress™ 2024, showcasing collaborative efforts with EF CLIF to advance understanding of ACLF pathophysiology and treatment approaches Liver Diseases GENFIT ACLF Research EASL Congress 2024 EF CLIF Partnership
BRIEF published on 05/14/2024 at 22:15, 6 months 6 days ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
PRESS RELEASE published on 05/14/2024 at 22:10, 6 months 6 days ago GENFIT Reports First Quarter 2024 Financial Information GENFIT reports Q1 2024 financial information showing cash position of €74.0 million and revenues of €1.1 million. Company expects cash to fund operations until Q4 2025 Financial Information Revenues Cash Position Q1 2024 GENFIT
Published on 11/21/2024 at 13:30, 21 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 21 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 51 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 51 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 51 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 16 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 36 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 53 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 31 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 6 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 6 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
